PERRIGO Co plc Annual Report - A Year in Review

Perrigo Co plc has undergone significant strategic shifts this past year. This summary distills key insights from their latest annual report for the fiscal year ended December 31, 2023, offering a clear, jargon-free overview for investors.

1. What Perrigo Does and Its Recent Performance

Perrigo is a global leader in Consumer Self-Care products, focusing on over-the-counter (OTC) health and wellness solutions. The company operates primarily through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSI).

Both segments offer a broad range of products across various categories, including:

• Upper Respiratory (e.g., cold and flu remedies)
• Digestive Health
• Nutrition (e.g., infant formula)
• Pain and Sleep Aids
• Healthy Lifestyle
• Oral Care
• Skincare and Personal Hygiene
• Women's Health
• Vitamins, Minerals, and Supplements (VMS)

Perrigo also maintains a Contract Manufacturing segment, which leverages its manufacturing capabilities to produce products for other companies, contributing a smaller but stable revenue stream.

Overall Performance: For fiscal year 2023, Perrigo reported net sales of approximately $4.6 billion, a slight decrease of 1.5% from $4.7 billion in 2022. This performance reflects a challenging market environment and the impact of strategic portfolio changes.

2. Financial Performance: Revenue, Profit, and Growth Metrics

Perrigo's financial results for the fiscal year ended December 31, 2023, presented a mixed picture:

• Net Sales: Approximately $4.6 billion, a 1.5% decrease from $4.7 billion in the prior year. This decline resulted from a combination of divestitures and some softness in specific product categories, partially offset by pricing actions.
• Gross Profit: Approximately $1.6 billion, leading to a gross margin of 34.8%.
• Operating Income: Approximately $350 million, significantly impacted by non-cash charges.
• Net Income (Loss): The company reported a net loss of approximately $120 million, or ($0.33) per diluted share. This loss was primarily due to substantial asset impairment charges. In contrast, Perrigo reported a net income of $180 million, or $0.49 per diluted share, in 2022.
• Adjusted Diluted EPS: Perrigo reported Adjusted Diluted EPS of $2.50. This metric excludes the impact of non-recurring items like impairment charges and divestiture-related costs, offering a clearer view of underlying operational performance.

Asset impairment charges significantly impacted reported profit, totaling approximately $450 million in 2023. These charges primarily related to certain intangible assets within the Consumer Self-Care Americas segment, reflecting revised market expectations for specific product lines. The company also reported "Other Operating Income/Loss, Net" of approximately $(50) million, which includes various gains and losses from non-core activities.

3. Major Wins, Challenges, and Future Strategy

The past year and the near future have been marked by significant strategic portfolio reshaping:

Strategic Wins & Future Expansion:

• Acquisition of Richard Bittner Business: In April 2025 (after the fiscal year ended), Perrigo acquired the Richard Bittner Business for approximately €120 million. This move is expected to strengthen its European Consumer Self-Care portfolio, particularly in the cough and cold category.

Challenges & Strategic Divestitures (Completed and Planned): Perrigo has actively streamlined its business to focus on its core Consumer Self-Care segments.

• Rare Diseases Business: Perrigo sold this business in July 2024 (after the fiscal year ended) for approximately $750 million in gross proceeds. This divestiture significantly reduces the company's exposure to the specialty pharmaceuticals market.
• Hospital Specialty Business: The company sold this business in November 2024 (after the fiscal year ended) for approximately $200 million in gross proceeds, further narrowing its focus to consumer health.
• Dermacosmetics Business: Perrigo forecasts selling this business by mid-2026 (specifically by July 13, 2026). This ongoing process indicates a continued commitment to optimizing the portfolio.
• RX Pharmaceuticals Business: The company sold this business in July 2021, and it is now classified as a discontinued operation, reflecting an earlier strategic shift away from prescription drugs.
• Asset Impairment Charges: As mentioned, Perrigo recognized $450 million in impairment charges in 2023. Further charges are anticipated, with approximately $70 million projected for 2024 and $90 million for 2025, including an impairment related to Kazmira LLC in late 2025. These charges reflect ongoing re-evaluation of asset values and indicate that some assets or business units have not performed to original expectations.

These divestitures and the targeted acquisition underscore a clear strategic pivot towards becoming a more focused and agile consumer health company.

4. Financial Health: Cash, Debt, and Liquidity

Perrigo actively manages its financial position and risks:

• Cash and Cash Equivalents: As of December 31, 2023, the company held approximately $280 million in cash and cash equivalents.
• Operating Cash Flow: Perrigo generated approximately $320 million in cash from operations during 2023, demonstrating healthy cash flow despite the net loss.
• Total Debt: The company had total debt of approximately $4.1 billion at year-end 2023, primarily consisting of Public Bonds and Private Placements.
• Liquidity: Perrigo maintains access to a revolving credit facility for additional liquidity. The company expects to use proceeds from recent and planned divestitures to reduce debt and make strategic investments, improving financial flexibility.
• Risk Management: Perrigo uses various financial derivatives (such as Foreign Exchange Forwards, Currency Swaps, and Interest Rate Swaps) to hedge against currency fluctuations and interest rate volatility, which is crucial for an international company. Specifically, it uses currency swaps for "net investment hedging" to protect the value of its foreign assets.

5. Key Risks That Could Affect Stock Price

Investors should be aware of several key risks:

• Asset Impairment Charges: The recurring and significant impairment charges (totaling $450 million in 2023, with more projected for 2024 and 2025) suggest potential overvaluation of assets or underperformance in certain business units. Further write-downs could negatively impact future earnings and investor confidence.
• Strategic Transition Execution: While portfolio reshaping is strategic, the process of divesting businesses and integrating new acquisitions carries risks. These include execution delays, unexpected costs, integration challenges, and potential disruption to operations or loss of key personnel.
• Competitive Pressures: The consumer health market is highly competitive, with numerous global and local players. Perrigo faces risks from new product introductions, aggressive pricing, and shifts in consumer preferences towards alternative health solutions.
• Regulatory and Compliance Risks: As a pharmaceutical and consumer health company, Perrigo is subject to extensive regulations (e.g., FDA in the U.S., EMA in Europe). Changes in regulations, product recalls, or non-compliance could lead to significant fines, reputational damage, and operational disruptions.
• Economic and Market Conditions: Factors like inflation, supply chain disruptions, rising interest rates, and changes in consumer spending habits can impact demand for Perrigo's products and increase operating costs.
• Market Valuations: The company's internal valuations for its segments rely on assumptions like "long-term revenue growth rate," "discount rate," and "revenue multiple." If these assumptions prove too optimistic or market conditions deteriorate, they could trigger further impairments or impact the perceived value of the company.

6. Competitive Positioning

Perrigo holds a strong position in the global consumer self-care market, particularly in store-brand OTC products and infant formula. Its diversified portfolio across categories like Upper Respiratory, Digestive Health, and Skincare highlights its strong presence in the health and wellness sector.

• Market Share: Perrigo is a leading provider of store-brand OTC products in the U.S. and a significant player in the European consumer health market. Its acquisition of Richard Bittner further strengthens its presence in key European categories.
• Brand Strength: While known for store brands, Perrigo also owns several established consumer brands. Its focus on essential health and wellness products provides a degree of resilience.
• Distribution Network: Extensive distribution channels across pharmacies, mass merchandisers, and online platforms provide broad market access.
• Innovation: Continuous investment in R&D for new product formulations and line extensions is crucial to maintaining competitiveness.

Perrigo's strategic divestitures indicate a clear intent to focus resources on areas where it believes it can achieve leading positions and sustainable growth, allowing it to better compete against rivals like Johnson & Johnson, Bayer, Haleon, and other generic and branded OTC manufacturers.

7. Leadership and Strategy Changes

The significant series of divestitures (Rare Diseases, Hospital Specialty, planned Dermacosmetics) and the targeted acquisition of the Richard Bittner Business strongly indicate a major strategic transformation initiated and executed by Perrigo's leadership. This represents a fundamental reshaping of the company's portfolio, aiming to create a more focused, consumer-centric self-care company.

This strategic shift aims to:

• Simplify the business model: Reducing complexity by shedding non-core assets.
• Improve profitability: Focusing on higher-margin, more predictable consumer health segments.
• Enhance financial flexibility: Using divestiture proceeds to reduce debt and invest in core growth areas.
• Optimize capital allocation: Directing resources towards areas with the highest growth potential in consumer self-care.

This restructuring reflects a clear strategic decision by the current leadership team to optimize the company's portfolio and unlock long-term shareholder value.

8. Future Outlook

Perrigo's future outlook centers on leveraging its streamlined portfolio and strong positions in core Consumer Self-Care categories.

• Strategic Focus: The company expects to complete its portfolio transformation by mid-2026 with the planned sale of the Dermacosmetics Business, allowing for a sharper focus on its Consumer Self-Care Americas and International segments.
• Growth Drivers: Management anticipates growth from strategic pricing, new product introductions, and market share gains in key categories like infant formula, digestive health, and VMS. The acquisition of Richard Bittner is expected to contribute to international growth.
• Financial Guidance: For fiscal year 2024, Perrigo has provided guidance for net sales growth in the low single digits and Adjusted Diluted EPS in the range of $2.60 to $2.80, reflecting the impact of divestitures and ongoing operational improvements.
• Debt Reduction: Perrigo expects proceeds from divestitures to significantly reduce debt, improving the balance sheet and potentially lowering interest expenses.
• Long-term Vision: The company uses "long-term revenue growth rates" as a key input for its segment valuations, indicating an internal projection for sustained growth within its core Consumer Self-Care businesses, aiming for mid-single-digit organic growth over the long term.

9. Market Trends and Regulatory Changes Affecting Perrigo

As a major player in consumer health, Perrigo is significantly influenced by several market trends and regulatory dynamics:

• Consumer Shift to Self-Care: A growing global trend towards self-medication and preventative health, driven by aging populations, rising healthcare costs, and increased health awareness, directly benefits Perrigo's core business.
• E-commerce Growth: The increasing adoption of online retail for health and wellness products presents both an opportunity for expanded reach and a challenge requiring robust digital strategies.
• Demand for Natural & Sustainable Products: Consumers are increasingly seeking products with natural ingredients and sustainable packaging, pushing companies to innovate and adapt their offerings.
• Regulatory Scrutiny: The consumer health sector faces ongoing regulatory oversight regarding product safety, labeling claims, and advertising. Changes in regulations, particularly from the FDA in the U.S. and the EMA in Europe, can impact product development, marketing, and market access.
• Supply Chain Volatility: Global events can impact the availability and cost of raw materials and manufacturing, affecting production and profitability.
• Economic Headwinds: Inflation and reduced consumer spending power could impact demand for discretionary health products, though essential OTC items tend to be more resilient.

Perrigo's strategic focus on its core consumer health segments positions it to capitalize on these favorable long-term trends while navigating the associated regulatory and competitive challenges.